

WEB TABLES

Table A Ischaemic heart disease events and strokes in trials of ≥ 6 months' duration low dose (50-125 mg/day) aspirin: individual trial data and summary odds ratios

Pre-existing disease	Dose (mg)	Duration (y)	Number of subjects		Ischaemic heart disease events						Strokes									
			aspirin	placebo	death		non-fatal infarct		Fatal and non-fatal		death		non-fatal		fatal and non-fatal		thrombotic		haemorrhagic	
					aspirin	placebo	aspirin	placebo	aspirin	placebo	aspirin	placebo	aspirin	placebo	aspirin	placebo	aspirin	placebo	aspirin	placebo
Ischaemic heart disease																				
RISC[w1]	75	1.0	474	471	9	16	33	67	42	83								1	0	
Juul-Möller[w2][w16]	75	4.2	1009	1026	34	46	47	78	81	124	7	11	21	27	28	38	23	36	6	2
Yasue[w3]	81	1.3	250	230	4	5	4	13	8	18	2	0	1	3	3	3	2	3	1	0
Hockings[w4][w16]	100	0.5	72	72			2	2					0	0						
Taylor[w5][w16]	100	0.5	124	128			0	2												
Cerebrovascular disease																				
Diener[w6][w16]	50	2.0	1649	1649	22	16	17	29	39	45	39	43	167	207	206	250				
Boysen[w7]	54	1.9	150	151			0	2			0	0	8	12	8	12				
SALT[w8]	75	2.7	676	684	18	28	36	40	54	68	16	10	77	102	93	112	82	105	11	4
Lindblad[w9]	75	0.5	117	115	0	3									10	18				
Atrial fibrillation																				
Posada[w10]	62.5 or 125	1.5	194	91	3	5					2	0	3	3	5	3	1	0	1	0
Petersen[w11][w16]	75	1.0	336	336							3	4	10	13	13	17	13	17	0	0
None (Healthy subjects)																				
Hansson[w12]	75	3.8	9399	9391					82	127					146	148			14	15
MRC[w13]	75	6.8	1268	1272	39	42	44	65	83	107	6	2	12	24	18	26	10	18	3	2
PPP[w14]	100	3.6	2226	2269	4	6	15	22	19	28	1	6	15	18	16	24			4	3
Summary odds ratio					0.79		0.62		0.68		0.99		0.77		0.84		0.74		1.52	
(95% confidence interval)					(0.63 to 0.98)		(0.52 to 0.74)		(0.60 to 0.77)		(0.72 to 1.35)		(0.67 to 0.88)		(0.75 to 0.93)		(0.59 to 0.91)		(0.94 to 2.46)	

* The expansion of acronyms is given in the citations; only first authors cited.
Blanks signify no available data

Table B Extra-cranial adverse effects in trials of low dose (50-125 mg/day) aspirin

Trial*	Daily dose (mg)	Number of subjects		Symptoms sufficient to stop tablets		Non-fatal major bleed †		Fatal bleed		Haematemesis or medaena		Any bleed		Upper abdominal discomfort (including heartburn)	
		aspirin	placebo	aspirin	placebo	aspirin	placebo	aspirin	placebo	aspirin	placebo	aspirin	placebo	aspirin	placebo
RISC[w1]	75	474	471	12	2	0	0	0	0	0	0	3	0	15	11
Juul-Möller[w2][w16]	75	1009	1026	109	100	18	11	5	4	11	6	21	14	47	44
Yasue[w3]	81	250	230												
Hockings[w4]	100	72	72	1	0	6	4			0	0				
Taylor[w5]	100	124	128	2	2	0	0	0	0	0	0				
Diener[w6]	50	1649	1649	141	127	16	10	1	2	25	19	135	74	502	465
Boysen[w7]	54	150	151	4	7	0	0								
SALT [w8][w16]	75	676	684	17	10	3	1			11	4	39	19	85	73
Lindblad[w9]	75	117	115	9	5	0	0	0	0	0	0				
Posada[w10]	62.5 or 125	194	91	13	0			0	0						
Petersen[w11][w16]	75	336	336	8	6	1	0	0	0	1	0	2	0	4	3
Hansson[w12]	75	9399	9391					5	5	107	55	278	150		
MRC[w13]	75	1268	1272	161 γ	126 γ	5	2	1	1	21	9	537	434		
PPP[w14]	100	2226	2269					1	3	17	5				
Silagy[w15]**	100	200	200	5	0	1	0	0	0	6	0	34	19	36	25

* The expansion of acronyms is given in the citations; only first authors cited
† Requiring blood transfusion or surgery
** No vascular events occurred
 γ Personal communication, A Rudnicka
Blanks signify no available data